WHAT YOU NEED TO KNOW Thanks to the bipartisan efforts of U.S. Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT), who are among those in both parties working to end Big Pharma’s exploitation of American patients, the big drug companies are on the defensive as support grows to address Big Pharma’s rampant patent abuse. On […]

Continue Reading

N CASE YOU MISSED IT: On Wednesday, Law360 published the below op-ed by intellectual property attorneys Stacie Ropka, Ted Mathias, and Chantelle Ankerman. Their op-ed highlights Big Pharma’s use of patent thickets to abuse the patent system and details how drugmaker Abbive has erected patent thickets around its best-selling drug, Humira. Humira was first licensed by the Food and […]

Continue Reading

IN CASE YOU MISSED IT: Yesterday, Axios highlighted a report from the Institute for Clinical and Economic Review (ICER), which found that drugmakers are not raising the prices on their products due to increased quality or safety, but simply because they can. For example, Humira, the world’s best-selling prescription drug, saw a $1.9 billion increase in net spending attributable […]

Continue Reading

WHAT YOU NEED TO KNOW In case you missed it, Michael Carrier, professor of law at Rutgers Law School and Genevieve Tung, associate director of the Rutgers Law Library, published an op-ed in Stat News on September 26 debunking Big Pharma’s disingenuous opposition of reforming the patent system. The pair encourages lawmakers to stand up to Big […]

Continue Reading